Logo do repositório
 
Publicação

MARVEL-minimising the emergence and dissemination of HIV-1 drug resistance in Portuguese-speaking African Countries (PALOP)

2024-12Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorSebastião, Cruz S.
dc.contributor.authorPingarilho, Marta
dc.contributor.authorBathy, Jamila
dc.contributor.authorBonfim, Elizângela
dc.contributor.authorToancha, Katia
dc.contributor.authorMiranda, Mafalda N. S.
dc.contributor.authorMartins, M. Rosário O.
dc.contributor.authorGomes, Perpétua
dc.contributor.authorLázaro, Lazismino
dc.contributor.authorPina-Araújo, Isabel
dc.contributor.authorNhampossa, Tacilta
dc.contributor.authorLeal, Silvania
dc.contributor.authorAbecasis, Ana B.
dc.contributor.authorPimentel, Victor
dc.contributor.institutionLaboratório Associado de Translacção e Inovação para a Saúde Global - LA Real (Pólo IHMT)
dc.contributor.institutionTB, HIV and opportunistic diseases and pathogens (THOP)
dc.contributor.institutionGlobal Health and Tropical Medicine (GHTM)
dc.contributor.institutionInstituto de Higiene e Medicina Tropical (IHMT)
dc.contributor.institutionPopulation health, policies and services (PPS)
dc.contributor.pblSpringer Verlag
dc.date.accessioned2024-09-30T22:30:50Z
dc.date.available2024-09-30T22:30:50Z
dc.date.issued2024-12
dc.descriptionFunding Information: Foundation for Science and Technology (FCT) funded the MARVEL project (PTDC/SAU-PUB/4018/2021), GHTM (GHTM-UID/04413/2020), LA-REAL-LA/P/0117/2020 supporting the costs related to project implementation in Cape Verde, Mozambique and Sao Tome & Principe. Calouste Gulbenkian Foundation (FCG), under the ENVOLVE Ci\u00EAncia PALOP program, funded the HITOLA project (Number 250466), which is supporting the costs related to the project implementation in Angola. The funders have no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript. Publisher Copyright: © The Author(s) 2024.
dc.description.abstractBackground: HIV-1 infections remain a global public health concern. Scaled-up antiretroviral treatment (ART) is crucial for reducing morbidity and mortality related to HIV/AIDS. The emergence of drug-resistance mutations (DRMs) compromises viral suppression and contributes to the continued HIV-1 transmission. Several reports indicate a recent increase in acquired (ADR) and transmitted (TDR) drug resistance in Africa, probably linked to the lack of implementation of HIV drug resistance (HIVDR) testing and suboptimal treatment adherence. Herein, we will develop a low-cost protocol using third-generation sequencing (Oxford Nanopore Technology) for HIV-1 surveillance in Portuguese-speaking African Countries - PALOP [Angola (AO), Cape Verde (CV), Mozambique (MZ), and Sao Tome & Principe (STP)]. Methods: This is a multicentric cross-sectional study that includes around 600 adult patients newly diagnosed with HIV-1 in the PALOP. An epidemiological questionnaire previously validated by our research team will be used to collect sociodemographic and clinical data. Also, whole blood samples will be collected and the plasma samples will be subjected to drug resistance testing using an in-house low-cost NGS protocol. Data analysis will involve bioinformatics, biostatistics and machine learning techniques to generate accurate and up-to-date information about HIV-1 genetic diversity, ADR and TDR. Discussion: The implementation of this low-cost NGS platform for HIV-1 surveillance in the PALOP will allow: (i) to increase DRM surveillance capacity in resource-limited settings; (ii) to understand the pattern and determinants of dissemination of resistant HIV-1 strains; and (iii) to promote the development of technical and scientific skills of African researchers for genomic surveillance of viral pathogens and bioinformatics analysis. These objectives will contribute to reinforcing the capacity to combat HIV infection in Africa by optimizing the selection of ART regimens, improving viral suppression, and reducing ADR or TDR prevalence in PALOPs, with relevant implications for public health.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent1390044
dc.identifier.doi10.1186/s12879-024-09803-1
dc.identifier.issn2374-4235
dc.identifier.otherPURE: 99693418
dc.identifier.otherPURE UUID: 8001f73d-c81b-4292-a2e6-c5a5f2f98164
dc.identifier.otherScopus: 85202873094
dc.identifier.otherWOS: 001303657800007
dc.identifier.otherPubMed: 39210296
dc.identifier.otherPubMedCentral: PMC11360575
dc.identifier.otherORCID: /0000-0002-7941-0285/work/168642457
dc.identifier.urihttp://hdl.handle.net/10362/172724
dc.identifier.urlhttps://www.scopus.com/pages/publications/85202873094
dc.language.isoeng
dc.peerreviewedyes
dc.subjectAfrica
dc.subjectDrug resistance
dc.subjectHIV-1
dc.subjectMachine learning
dc.subjectPALOP
dc.subjectInfectious Diseases
dc.subjectSDG 3 - Good Health and Well-being
dc.titleMARVEL-minimising the emergence and dissemination of HIV-1 drug resistance in Portuguese-speaking African Countries (PALOP)en
dc.title.subtitlelow-cost portable NGS platform for HIV-1 surveillance in Africaen
dc.typejournal article
degois.publication.issue1
degois.publication.titleBMC Infectious Diseases
degois.publication.volume24
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
MARVEL-minimising_the_emergence_and_dissemination_of_HIV-1_drug_resistance_in_Portuguese-speaking_African_Countries_PALOP_low-cost_portable_NGS_platform_for_HIV-1_surveillance_in_Africa.pdf
Tamanho:
1.33 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

Home collection (IHMT)